LEM-mR203
- Generic Name
- LEM-mR203
Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)
Phase 1
Completed
- Conditions
- COVID-19 Vaccine Adverse ReactionCOVID-19 Infection
- Interventions
- Biological: Placebo
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Lemonex
- Target Recruit Count
- 20
- Registration Number
- NCT06032000
- Locations
- 🇰🇷
Seoul National University Hospital Clinical Trials Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath